How are Ipamorelin and CJC-1295 studied together?
Ipamorelin (a GHRP / ghrelin-receptor agonist) and CJC-1295 (a GHRH analog) act on complementary arms of the GH axis. Researchers combine them in preclinical models to study pulsatile growth hormone release.
The growth-hormone (GH) axis is regulated by two opposing peptides released from the hypothalamus: GHRH (growth-hormone-releasing hormone) and somatostatin (inhibitory). Ipamorelin and CJC-1295 are research peptides that target this axis from two different angles.
Ipamorelin
- A selective ghrelin-receptor (GHS-R1a) agonist — a "GHRP" class peptide.
- Studied for its ability to stimulate GH release without significant effects on cortisol or prolactin in preclinical models.
CJC-1295
- A GHRH analog. Modified versions extend its half-life by binding albumin.
- Studied for its ability to amplify the endogenous pulsatile pattern of GH release.
The two are mechanistically complementary: Ipamorelin acts on the ghrelin receptor while CJC-1295 acts on the GHRH receptor, and the combination has been used in research to study synergistic GH release. Both are supplied for RUO laboratory investigation only.
See the Performance pathway for the full GH-axis catalog.
// Related research pathways